Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome

  • Merle Fernandes
  • Divya Vira
  • Radhika Medikonda
  • Nagendra Kumar
Cornea

Abstract

Background

Emergence of multi-drug resistant (MDR), extensively drug resistant (XDR), and pan-drug resistant (PDR) strains of Pseudomonas aeruginosa pose a significant therapeutic challenge. Managing XDR and PDR Pseudomonas aeruginosa keratitis would be extremely difficult due to paucity of safe and effective topical medications. We aim to describe the clinical features, risk factors, and outcome of XDR and PDR Pseudomonas aeruginosa keratitis.

Methods

A retrospective chart review of consecutive cases of XDR and PDR Pseudomonas aeruginosa keratitis were identified from Ocular Microbiology Department. XDR and PDR were defined based on criteria established by Centers for Disease Control and European Centre for Disease Prevention and Control. The following data was collected: age, gender, occupation, symptom duration, systemic and ocular risk factors, infiltrate characteristics, antimicrobial susceptibility, complications, surgical interventions, presenting, and final visual acuity and final outcome. Complete success was defined as resolution of the infiltrate with scar formation on medical treatment alone. Partial success was the resolution following tissue adhesive application. Failure was an inadequate response to medical therapy with progressive increase in infiltrate, corneal melting, and/or perforation necessitating one or more therapeutic penetrating keratoplasties or evisceration.

Results

Fifteen eyes of 13 patients were included. Seven (53.8 %) were male with left eye involvement in nine (60 %) cases. Most common risk factors were bandage contact lens (6, 40 %), topical steroids (5, 33.3 %), previous therapeutic graft (4, 26.6 %), and ocular surface disorder (OSD) following Stevens Johnson Syndrome (SJS) (4, 26.6 %). Of 15 isolates, six (40 %) were sensitive only to imipenem, three (20 %) to colistin, two (13.3 %) to neomycin, one (6.7 %) each to imipenem and colistin, imipenem and ceftazidime, and azithromycin respectively. One isolate was resistant to all antibiotics. Complete success was noted in two (16.67 %), partial success in three (25 %) and failure in seven (58.33 %) eyes. Five (33.3 %) eyes healed on imipenem (three eyes), azithromycin (one eye), and imipenem and colistin (one eye).

Conclusion

XDR and PDR Pseudomonas aeruginosa keratitis are extremely difficult to treat. Globe salvage was possible in all cases; however, more than half required therapeutic grafts. Close monitoring of patients with known ocular and systemic factors is warranted.

Keywords

Pseudomonas aeruginosa Microbial keratitis Extensive drug resistance Multi-drug resistance Pan-drug resistance 

Notes

Acknowledgments

We would like to acknowledge Dr. Savitri Sharma, MD, Jhaveri Centre for Microbiology, L V Prasad Eye Institute, Hyderabad for reviewing the manuscript and providing feedback.

We would also like to acknowledge Mr. Mohammed Hasnat Ali, MBA, Biostatistician, L V Prasad Eye Institute, Hyderabad for inputs on the statistical analysis.

Compliance with ethical standards

Funding

No funding was received for this research.

Conflict of Interest

All authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. In this retrospective study formal consent was not required. There is no identifying information available in the article.

References

  1. 1.
    Whitcher JP, Srinivasan M, Upadhyay MP (2001) Corneal blindness: a global perspective. Bull World Health Organ 79:214–21PubMedPubMedCentralGoogle Scholar
  2. 2.
    Gopinathan U, Sharma S, Garg P, Rao GN (2009) Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. Ind J Ophthalmol 57(4):273–79CrossRefGoogle Scholar
  3. 3.
    Bharathi M, Ramakrishna R, Shivakumar C, Meenakshi R, Lionalraj D (2010) Etiology and antibacterial susceptibility pattern of community acquired bacterial ocular infections in a tertiary eye care hospital in south India. Ind J Ophthalmol 58(6):497–507CrossRefGoogle Scholar
  4. 4.
    Garg P, Sharma S, Rao GN (1999) Ciprofloxacin-resistant pseudomonas keratitis. Ophthalmology 106:1319–1323PubMedCrossRefGoogle Scholar
  5. 5.
    Jhanji V, Sharma N, Satpathy G, Titiyal J (2007) Fourth-generation fluoroquinolone resistant bacterial keratitis. J Cataract Ref Surg 33:1488–89CrossRefGoogle Scholar
  6. 6.
    Park SH, Lim JA, Choi JS, Kim KA, Joo CK (2009) The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea 28:68–72PubMedCrossRefGoogle Scholar
  7. 7.
    Nordmann P, Naas T, Fortineau N, Poirel L (2007) Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 10(5):436–40PubMedCrossRefGoogle Scholar
  8. 8.
    Magiorakos AP, Srinivasan R, Carey RB, Carmell Y, Falagas MR, GIske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Inf 18:268–281CrossRefGoogle Scholar
  9. 9.
    Ku JY, Kim P, Tong J, Wechsler A, McCluskey P (2010) Multiresistant Pseudomonas keratitis. Clin Exp Ophthalmol 38(8):818–819CrossRefGoogle Scholar
  10. 10.
    Jain R, Murthy SI, Motukupally SR (2014) Clinical outcomes of corneal graft infections caused by multi-drug resistant Pseudomonas aeruginosa. Cornea 33(1):22–26PubMedCrossRefGoogle Scholar
  11. 11.
    Chaurasia S, Ramappa M, Ashar J, Sharma S (2014) Neonatal infectious keratitis. Cornea 33(7):673–676PubMedCrossRefGoogle Scholar
  12. 12.
    Jain R, Murthy SI, Motukupally SR, Jain M (2014) Use of topical colistin in multiple drug resistant Pseudomonas aeruginosa bacterial keratitis. Cornea 33(9):923–927PubMedCrossRefGoogle Scholar
  13. 13.
    Sharma S, Gopalakrishnan S, Aasuri MK, Garg P, Rao GN (2003) Trends in contact lens-associated microbial keratitis in South India. Ophthalmology 110:138–143PubMedCrossRefGoogle Scholar
  14. 14.
    Dart JKG, Seal DV (1988) Pathogenesis and therapy of Pseudomonas aeruginosa keratitis. Eye 2(Suppl):S46–S55PubMedCrossRefGoogle Scholar
  15. 15.
    American Academy of Ophthalmology Cornea/External Disease Panel (2013) Bacterial keratitis preferred practice pattern. American Academy of Ophthalmology 1–42Google Scholar
  16. 16.
    Hooper DC (2000) Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Inf Dis 31(Suppl 2):S24–8CrossRefGoogle Scholar
  17. 17.
    Oldenburg CE, Prajna L, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J et al (2013) Emerging Moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India. Ophthalmic Epidemiol 20(3):155–158PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Gonzalez-Costello J et al (2014) Extensively drug resistant Pseudomonas aeruginosa bacteremia in solid organ transplant. Transplantation 99(3):616–22CrossRefGoogle Scholar
  19. 19.
    Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L (2003) Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Oophthalmol 87:834–838CrossRefGoogle Scholar
  20. 20.
    Bharati JM, Ramakrishnan R, Meenakshi R, Shivakumar C, Raj DL (2009) Analysis of the risk factors predisposing to fungal, bacterial, and Acanthamoeba keratitis in south India. Indian J Med Res 130:749–757Google Scholar
  21. 21.
    Stapleton F, Carnt N (2012) Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. Eye 26:185–193PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Stapleton F, Keaty L, Edwards K, Naduvilath T, Dart JK, Brian G et al (2008) The incidence of contact lens-related microbial keratitis in Australia. Ophthalmology 115:1665–1662CrossRefGoogle Scholar
  23. 23.
    Bruinsma GM, van der Mei HC, Busscher HJ (2001) Bacterial adhesion to surface hydrophilic and hydrophobic contact lenses. Biomaterials 22:3217–3224PubMedCrossRefGoogle Scholar
  24. 24.
    Tam C, Mun JJ, Evans DJ, Fleiszig SMJ (2010) The impact of inoculation parameters on pathogenesis of contact lens-related infectious keratitis. Invest Ophthalm Vis Sci 51:3100–3106CrossRefGoogle Scholar
  25. 25.
    Ho PC, Elliott JH (1975) Kinetics of corneal epithelial regeneration.II. Epidermal growth factor and topical corticosteroids. Investig Ophthalmol 14(8):630–633Google Scholar
  26. 26.
    No authors listed (2007) The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop. Ocular Surf 5: 93–107Google Scholar
  27. 27.
    Jhanji V, Constantinou M, Taylor HR, Vajpayee RB (2009) Microbiological and clinical profiles of patients with microbial keratitis residing in nursing homes. Br J Ophthalmol 93:1639–1642PubMedCrossRefGoogle Scholar
  28. 28.
    Sotozono C, Inagaki K, Fujita A, Koizumi N, Sano Y, Inatomi T et al (2002) Methicillin-resistant Staphylococcus aureus and Methicillin-resistant Staphylococcus epidermidis in the cornea. Cornea 21(Suppl 2):S94–S101PubMedCrossRefGoogle Scholar
  29. 29.
    Nation RL, Li J (2009) Colistin in the 21st Century. Curr Opin Infect Dis 22(6):535–543PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Equi A, Balfour-Lynn IM, Bush A, Rosenthal M (2002) Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 360:978–84PubMedCrossRefGoogle Scholar
  31. 31.
    Bala A, Kumar R, Harjai K (2011) Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections. J Med Microbiol 60:300–306PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Merle Fernandes
    • 1
  • Divya Vira
    • 1
  • Radhika Medikonda
    • 1
  • Nagendra Kumar
    • 2
  1. 1.Cornea and Anterior Segment ServicesL. V. Prasad Eye InstituteVisakhapatnamIndia
  2. 2.Ocular Microbiology DepartmentL. V. Prasad Eye InstituteVisakhapatnamIndia

Personalised recommendations